Praveen K Bommareddy

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Herpes Simplex Virus

Dendritic Cells

Immune Response

Top Venues

Journal for immunotherapy of cancer

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for immunotherapy of cancer 12 (4) (2024)
Sachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, Praveen K Bommareddy, Jenna H Newman, Amanda L Marzo, Timothy M Kuzel, Vineet Gupta, Jochen Reiser, Preston Daniels, Devora Schiff, Darrion Mitchell, Nicole R LeBoeuf, Christopher Simmons, Sharad Goyal, Ahmed Lasfar, José A Guevara-Patiño, Bruce G Haffty, Howard L Kaufman, Ann W Silk, Andrew Zloza
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. Journal for immunotherapy of cancer 11 (7) (2023)
Laura Poillet-Perez, Daniel W Sharp, Yang Yang, Saurabh V Laddha, Maria Ibrahim, Praveen K Bommareddy, Zhixian Sherrie Hu, Joshua Vieth, Michael Haas, Marcus W Bosenberg, Joshua D Rabinowitz, Jian Cao, Jun-Lin Guan, Shridar Ganesan, Chang S Chan, Janice M Mehnert, Edmund C Lattime, Eileen P White
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature cancer 2 (9) (2022)
Laura Poillet-Perez, Daniel W Sharp, Yang Yang, Saurabh V Laddha, Maria Ibrahim, Praveen K Bommareddy, Zhixian Sherrie Hu, Joshua Vieth, Michael Haas, Marcus W Bosenberg, Joshua D Rabinowitz, Jian Cao, Jun-Lin Guan, Shridar Ganesan, Chang S Chan, Janice M Mehnert, Edmund C Lattime, Eileen P White
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature cancer 1 (9) (2020)
Praveen K Bommareddy, Salvatore Aspromonte, Andrew Zloza, Samuel D Rabkin, Howard L Kaufman
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science translational medicine 10 (471) (2019)
Praveen K Bommareddy, Samuel D Rabkin, Howard L Kaufman
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology 8 (4) (2019)
Praveen K Bommareddy, Andrew Zloza, Samuel D Rabkin, Howard L Kaufman
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 8 (7) (2019)